HuMax-TF-ADC

DRUG3 trials

Sponsors

Seagen Inc., Genmab A/S

Conditions

Locally Advanced or Metastatic Disease in Solid TumorsRecurrent or stage IVB cervical cancerSecond- or Third-Line Recurrent or Metastatic Cervical Cancer

Phase 1

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer

Active, not recruitingCTIS2023-508832-68-00

Genmab A/SRecurrent or stage IVB cervical cancer

Start: 2019-03-28Target: 143Updated: 2025-06-30

Phase 2

C5721001 - Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Active, not recruitingCTIS2023-503812-34-00

Seagen Inc.Locally Advanced or Metastatic Disease in Solid Tumors

Start: 2019-02-13Target: 79Updated: 2026-01-12

Phase 3

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

CompletedCTIS2023-503813-31-01

Seagen Inc.Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Start: 2021-09-17End: 2025-11-18Target: 188Updated: 2025-11-19